Recently, Xiling Lab Co., Ltd. (hereinafter referred to as "Xiling Lab") and BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene") have signed a strategic cooperation agreement on a high-end generic drug project.  At the signing ceremony, the two sides fully affirmed the remarkable achievements of cooperation over the past two years, and decided to give full play to their respective technical and resource advantages, and comprehensively enhance the depth and breadth of cooperation to accelerate the development and industrialization of high-end generic drugs to provide patients with reliable drugs at reasonable prices.  At the same time, the two sides discussed upcoming cooperation projects.

Xiling Lab is a biopharmaceutical technology company driven by R & D innovation and win-win cooperation. With catalytic technology as the core of its drug research and development platform, this company focuses on the development of differentiated innovative drugs and high-end generic drugs.

BrightGene is a research and development-driven high-tech pharmaceutical company, dedicated to the development and production of original new drugs and high-end generic drugs. It provides patients with products of outstanding value through its professional product development and commercialization.  In November 2019, it was officially listed on the Shanghai Stock Exchange's Innovation Board (stock code: 688166).

Mr. Huang Jinkun, Chairman and General Manager of Xiling Lab; Mr. Xie Dejian, Director and Chief Operating Officer of Xinling Lab; Mr. Yuan Jiandong, Chairman and General Manager of BrightGene; and Mr. Li Ming, Director of Business Development of BrightGene, attended the signing ceremony.

Signing Ceremony of the Strategic Cooperation Agreement Between Xiling Lab and BrightGene